Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Randomized Controlled Trial
. 2016 Feb 1;37(5):455-62.
doi: 10.1093/eurheartj/ehv464. Epub 2015 Sep 15.

Influence of ejection fraction on outcomes and efficacy of spironolactone in patients with heart failure with preserved ejection fraction

Scott D Solomon  1 , Brian Claggett  2 , Eldrin F Lewis  2 , Akshay Desai  2 , Inder Anand  3 , Nancy K Sweitzer  4 , Eileen O'Meara  5 , Sanjiv J Shah  6 , Sonja McKinlay  7 , Jerome L Fleg  8 , George Sopko  8 , Bertram Pitt  9 , Marc A Pfeffer  2 ; TOPCAT Investigators
Affiliations
Randomized Controlled Trial

Influence of ejection fraction on outcomes and efficacy of spironolactone in patients with heart failure with preserved ejection fraction

Scott D Solomon et al. Eur Heart J. .

Abstract

Aims: While mineralocorticoid receptor antagonists (MRAs) have been shown to benefit patients with reduced left ventricular ejection fraction (LVEF), spironolactone did not reduce the primary endpoint of cardiovascular death, heart failure hospitalization, or aborted cardiac arrest in patients with heart failure with preserved ejection fraction (HFpEF) in the TOPCAT trial, which enrolled patients with LVEF of 45% or greater. We utilized data from TOPCAT to assess the relationship between LVEF as well as outcomes and efficacy of spironolactone.

Methods and results: We assessed differences in baseline characteristics and outcomes across LVEF categories in 3444 patients with HFpEF, and determined whether LVEF modified the treatment effect of spironolactone. Ejection fraction ranged from 44 to 85%. Patients with higher ejection fraction were older, more likely to be female, less likely to have a history of myocardial infarction, and more likely to have a history of hypertension and diabetes. The incidence of the primary endpoint and cardiovascular death was highest in patients at the lower end of the ejection fraction spectrum. Ejection fraction modified the spironolactone treatment effect, particularly in the patients enrolled in the Americas, for the primary outcome (P = 0.046) and for heart failure hospitalization (P = 0.039), with stronger estimated benefits of spironolactone at the lower end of the ejection fraction spectrum with respect to the primary endpoint (LVEF <50%: HR 0.72, 95% CI 0.50, 1.05; LVEF ≥60%: HR 0.97, 95% CI 0.76, 1.23) and heart failure hospitalization (LVEF <50%: HR 0.76, 95% CI 0.46, 1.27; LVEF ≥60%: HR 0.98, 95% CI 0.74, 1.30).

Conclusion: In patients with HFpEF enrolled in TOPCAT, patient characteristics and outcomes varied substantially by LVEF. The potential efficacy of spironolactone was greatest at the lower end of the LVEF spectrum.

Clinicaltrialsgov number: NCT00094302.

Keywords: Heart failure with preserved ejection fraction; Spironolactone.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Distribution of ejection fractions.
Figure 2
Figure 2
Multivariable adjusted incidence rate (per 100 patient-years) by left ventricular ejection fraction for primary endpoint (upper left, P = 0.02), heart failure hospitalization (upper right, P = 0.79), cardiovascular death (lower left, P = 0.002), and all-cause death (lower right, P = 0.004).
Figure 3
Figure 3
Treatment effect as a function of ejection fraction for primary outcome (upper left panel), heart failure hospitalization (upper right panel), and cardiovascular death (lower panel). Dashed lines represent 95% confidence intervals.
Figure 4
Figure 4
Treatment effect for the primary outcome in men (blue) and women (red). Pinteraction = 0.077.
See this image and copyright information in PMC

Comment in

References

    1. Butler J, Fonarow GC, Zile MR, Lam CS, Roessig L, Schelbert EB, Shah SJ, Ahmed A, Bonow RO, Cleland JG, Cody RJ, Chioncel O, Collins SP, Dunnmon P, Filippatos G, Lefkowitz MP, Marti CN, McMurray JJ, Misselwitz F, Nodari S, O'Connor C, Pfeffer MA, Pieske B, Pitt B, Rosano G, Sabbah HN, Senni M, Solomon SD, Stockbridge N, Teerlink JR, Georgiopoulou VV, Gheorghiade M. Developing therapies for heart failure with preserved ejection fraction: current state and future directions. JACC Heart Fail 2014;2:97–112. - PMC - PubMed
    1. Yusuf S, Pfeffer MA, Swedberg K, Granger C, Held P, McMurray JJV, Michelson EL, Olofsson B, Ostergren J; Charm Investigators. Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the CHARMPreserved Trial . Lancet 2003;362:777–781. - PubMed
    1. Massie BM, Carson PE, McMurray JJ, Komajda M, McKelvie R, Zile MR, Anderson S, Donovan M, Iverson E, Staiger C, Ptaszynska A; I-PRESERVE Investigators. Irbesartan in patients with heart failure and preserved ejection fraction. N Engl J Med 2008;359:2456–2467. - PubMed
    1. Solomon SD, Anavekar N, Skali H, McMurray JJ, Swedberg K, Yusuf S, Granger CB, Michelson EL, Wang D, Pocock S, Pfeffer MA; Candesartan in Heart Failure Reduction in Mortality (CHARM) Investigators. Influence of ejection fraction on cardiovascular outcomes in a broad spectrum of heart failure patients. Circulation 2005;112:3738–3744. - PubMed
    1. Meta-analysis Global Group in Chronic Heart Failure (MAGGIC). The survival of patients with heart failure with preserved or reduced left ventricular ejection fraction: an individual patient data meta-analysis. Eur Heart J 2012;33:1750–1757. - PubMed

Publication types

Substances

Associated data